June 20, 2025
Source: drugdu
54
On June 13, AstraZeneca and CSPC Pharmaceutical Group reached a strategic cooperation. The two parties will focus on high-priority targets and work together to promote the discovery and development of new oral drug candidates.
CSPC Pharmaceutical Group will conduct research using its AI engine dual-driven efficient drug discovery platform. The platform uses AI technology to analyze the binding mode between target proteins and existing compound molecules and conduct targeted optimization, aiming to screen out small molecules that are highly efficient and have excellent development potential.
Under the agreement, CSPC Pharmaceutical Group will receive an upfront payment of US$110 million and will be eligible to receive potential research and development milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on annual net sales of the relevant products.
As a global pharmaceutical giant, AstraZeneca continues to exert its strength in the pharmaceutical market with its profound experience in drug research and development, clinical trials and marketing. As a large Chinese pharmaceutical company, CSPC Pharmaceutical Group has also demonstrated its strength in drug research and development, especially in the emerging field of AI-driven small molecule drug design platform, where it has made remarkable progress.
This cooperation is of great significance and will inject new vitality into the pharmaceutical industry in multiple dimensions.
In terms of drug research and development, the two parties have complementary advantages. The combination of AstraZeneca's deep industry background and Shijiazhuang Pharmaceutical Group's cutting-edge AI technology is expected to accelerate the development of new oral drug candidates and bring new treatment options to patients with various chronic diseases more quickly.
From the perspective of R&D efficiency, the deep integration of AI technology can accurately analyze massive data, accurately screen drug molecules, greatly improve the efficiency and accuracy of drug discovery, and thus effectively reduce R&D costs and time.
In terms of market expansion, AstraZeneca will use this cooperation to further enrich its product pipeline and enhance its competitiveness in the Chinese and global markets; CSPC Pharmaceutical Group will take this opportunity to demonstrate its innovative strength to the international market and further enhance its visibility and influence in the international pharmaceutical market.
More importantly, this strategic cooperation provides a valuable example for the in-depth cooperation between industry, academia and research in the pharmaceutical industry, strongly promotes the deep integration of AI technology and drug research and development, and leads the entire pharmaceutical industry to move towards intelligent and efficient innovative development, contributing key forces to the upgrading and development of the global pharmaceutical industry.
https://news.yaozh.com/archive/45635.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.